Rebecca J Cogswell1, Faye L Norby2, Rebecca F Gottesman3, Lin Y Chen1, Scott Solomon4, Amil Shah4, Alvaro Alonso5. 1. Division of Cardiology, University of Minnesota, Minneapolis, MN, USA. 2. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 3. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. 5. Division of Epidemiology and School of Public Health, Emory University, Atlanta, GA, USA.
Abstract
AIMS: Undetected atrial fibrillation (AF) may be common in the heart failure with preserved ejection fraction (HFpEF) population, and failure to detect this may lead to the missing of opportunities to prevent associated subclinical cerebral infarctions (SCIs) and cognitive decline. METHODS AND RESULTS: We studied 1527 participants in the Atherosclerosis Risk in Communities (ARIC) Study, who underwent echocardiography, brain magnetic resonance imaging (MRI) and detailed cognitive assessment during 2011-13. Prevalences of SCI as detected by brain MRI were compared among the following groups: participants with no HFpEF/no AF; those with no HFpEF/AF; those with HFpEF/no AF, and those with HFpEF/AF. Cognitive scores were also compared. Prevalences of HFpEF and AF in this sample were 13.2% and 5.7%, respectively. Participants with HFpEF but no prior diagnosis of AF had a high prevalence of SCI by brain MRI (29.3%), which was similar to those in the no HFpEF/AF (24.5%) and HFpEF/AF (23.5%) groups, but higher than that in the no HFpEF/no AF subjects (17.3%). The odds of having SCI were higher in participants with HFpEF/no AF than in the no HFpEF/no AF group even after adjustment for potential confounders (odds ratio 1.56, 95% confidence interval 1.06-2.30). Individuals with HFpEF and SCI had lower cognitive scores than the reference (no HFpEF/no SCI) and HFpEF/no SCI groups. CONCLUSIONS: Subclinical cerebral infarctions were prevalent in subjects in the ARIC cohort with HFpEF and no prior AF diagnosis and are associated with measurable cognitive deficits. Although other sources of emboli may be possible, these data suggest that paroxysmal AF may be underdiagnosed in this population. There may be a role for earlier anticoagulation in patients with HFpEF.
AIMS: Undetected atrial fibrillation (AF) may be common in the heart failure with preserved ejection fraction (HFpEF) population, and failure to detect this may lead to the missing of opportunities to prevent associated subclinical cerebral infarctions (SCIs) and cognitive decline. METHODS AND RESULTS: We studied 1527 participants in the Atherosclerosis Risk in Communities (ARIC) Study, who underwent echocardiography, brain magnetic resonance imaging (MRI) and detailed cognitive assessment during 2011-13. Prevalences of SCI as detected by brain MRI were compared among the following groups: participants with no HFpEF/no AF; those with no HFpEF/AF; those with HFpEF/no AF, and those with HFpEF/AF. Cognitive scores were also compared. Prevalences of HFpEF and AF in this sample were 13.2% and 5.7%, respectively. Participants with HFpEF but no prior diagnosis of AF had a high prevalence of SCI by brain MRI (29.3%), which was similar to those in the no HFpEF/AF (24.5%) and HFpEF/AF (23.5%) groups, but higher than that in the no HFpEF/no AF subjects (17.3%). The odds of having SCI were higher in participants with HFpEF/no AF than in the no HFpEF/no AF group even after adjustment for potential confounders (odds ratio 1.56, 95% confidence interval 1.06-2.30). Individuals with HFpEF and SCI had lower cognitive scores than the reference (no HFpEF/no SCI) and HFpEF/no SCI groups. CONCLUSIONS: Subclinical cerebral infarctions were prevalent in subjects in the ARIC cohort with HFpEF and no prior AF diagnosis and are associated with measurable cognitive deficits. Although other sources of emboli may be possible, these data suggest that paroxysmal AF may be underdiagnosed in this population. There may be a role for earlier anticoagulation in patients with HFpEF.
Authors: Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li Journal: Circ Heart Fail Date: 2012-12-20 Impact factor: 8.790
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Alvaro Alonso; Sunil K Agarwal; Elsayed Z Soliman; Marietta Ambrose; Alanna M Chamberlain; Ronald J Prineas; Aaron R Folsom Journal: Am Heart J Date: 2009-07 Impact factor: 4.749
Authors: Francesco Bianco; Raffaele De Caterina; Alvin Chandra; Iolanda Aquila; Brian Claggett; Michelle C Johansen; Alexandra Gonçalves; Faye L Norby; Rebecca Cogswell; Elsayed Z Soliman; Rebecca Gottesman; Thomas Mosley; Alvaro Alonso; Amil Shah; Scott D Solomon; Lin Yee Chen Journal: J Am Heart Assoc Date: 2022-05-02 Impact factor: 6.106
Authors: Michelle C Johansen; Amil M Shah; Seth T Lirette; Michael Griswold; Thomas H Mosley; Scott D Solomon; Rebecca F Gottesman Journal: J Am Heart Assoc Date: 2018-12-18 Impact factor: 5.501
Authors: Camilo Toledo; Claudia Lucero; David C Andrade; Hugo S Díaz; Karla G Schwarz; Katherin V Pereyra; Alexis Arce-Álvarez; Nicolás A López; Milka Martinez; Nibaldo C Inestrosa; Rodrigo Del Rio Journal: Aging (Albany NY) Date: 2019-08-25 Impact factor: 5.682